IL1B and breast carcinoma: Taking our new data together with these studies and previous studies showing near elimination of bone metastasis with Canakinumab and Anakinra, inhibiting IL1β or preventing IL1β binding to its receptor IL1R appears to almost prevent metastatic outgrowth of breast cancer in the bone [2,9,12,13].